U.S. Food and Drug Administration issued an advisory on the safety of erythropoiesis-stimulating agents darbepoetin alfa and epoetin alfa. The new safety information contains revised product labeling that includes updated warnings, a new boxed warning, and changes to dosing instructions. The boxed warning advises physicians to monitor hemoglobin levels and adjust the dose of erythropoiesis-stimulating agents to maintain hemoglobin levels needed to avoid blood transfusion.
According to the report, Use Of Erythropoiesis Stimulating Agents In Treating Parkinsonís Disease is one of the primary growth factors for the market. Increasing Occurrence of Chronic Kidney Disease (CKD)
is also expected to contribute significantly to the Erythropoiesis Stimulating Agents market. Overall, Cancer
applications of Erythropoiesis Stimulating Agents, and the growing awareness of them, is what makes this segment of the industry important to its overall growth. The Dosage, such as 2000-4000 IU, is boosting the Erythropoiesis Stimulating Agents market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.The Drug Class, such as Biologics, is boosting the Erythropoiesis Stimulating Agents market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.
AMAs Analyst on the Global Erythropoiesis Stimulating Agents market identified that the demand is rising in many different parts of the world as "Growing Use of in Erythropoiesis in Treating HIV Infections
". Furthermore, some recent industry insights like "In October 2019, the companies named JCR Pharmaceuticals, Chong Kun Dang Holdings, and Dong-A ST Co., Ltd. received approval for sale of their darbepoetin alfa biosimilars products in the Japanese market. Darbepoetin alfa stimulates the production of red blood cells (erythropoiesis). The majority of patients in Japan are undergoing chronic dialysis is expected to have erythropoiesis-stimulating agents for the treatment." is constantly making the industry dynamic.
The report provides an in-depth analysis and forecast about the industry covering the following key features: o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies o Analyses the Global Erythropoiesis Stimulating Agents market according to Type, Application, and regions o Analyzes the top 10 players in terms of market reach, business strategy, and business focus o Provides stakeholders insights and key drivers & trends of the market
**The market is valued based on weighted average selling price (WASP) and includes any applicable taxes on manufacturers. All currency conversions used in the creation of this report have been calculated using constant annual average 2020 currency rates.
o Key & emerging players in the market have been observed through secondary research. o The industrys supply chain and overall market size, in terms of value, have been derived through primary and secondary research processes. o All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation The overall Erythropoiesis Stimulating Agents market size is calculated using market estimation process, the Erythropoiesis Stimulating Agents market was further split into various segments and sub-segments. To complete the overall market engineering and arriving at the exact statistics for all segments and sub-segments, the market breakdown and data triangulation procedures have been utilized, wherever applicable. The data have been triangulated by studying various influencing factors and trends identified from both demand and supply sides of various applications involved in the study. Along with this, the Global Erythropoiesis Stimulating Agents market size has been validated using both top-down and bottom-up approaches.